Please assess the completion status of the following clinical trial:

Trial Title: Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criterion:~* Patients scheduled for elective or urgent CABG of two to six vessels~Exclusion Criteria:~Preoperative:~* Hemoglobin of less than 110g/L~* Under 18 years of age~* Body mass less than 75kg~* Presence of an intra-aortic balloon pump~* Emergency surgery, requiring operative intervention within 24 hours of consultation to the cardiac surgery team~* Need for cardiac surgical intervention in addition to planned CABG (with the exception of patent foramen ovale closure)~* Ejection fraction (EF) of less than 50%, as determined by echocardiogram or angiography~* Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg (as estimated by right ventricular systolic pressure (RVSP))~* Presence of infectious endocarditis~* Hepatic failure with impaired liver function, including International Normalized Ratio (INR) greater than 1.5~* Known diagnosed bleeding disorder~* History of heparin induced thrombocytopenia and thrombosis (HITT)~* Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with urine output less than 10ml/hour~* Allergy to tranexamic acid~* Pregnancy~Intraoperative:~* Discovery of infectious endocarditis~* Need for cardiac surgical intervention in addition to planned coronary CABG~* Development of allergic reaction to tranexamic acid following intravenous infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Trial Drug (Type: EXPERIMENTAL): Solution containing 2 grams tranexamic acid + normal saline
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).